^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR155 (MicroRNA 155)

    i
    Other names: MIR155, MicroRNA 155, MIRN155
    1d
    Functionally integrated palindromic hairpin-enabled signal efficient amplification and continuous transduction for one-pot miRNA sensing. (PubMed, J Photochem Photobiol B)
    Besides, owing to its high specificity and robustness, this method could clearly identify cancer cells from normal cells through analysis of cellular miRNA-155. Furthermore, the method can also be adapted to sense various miRNAs just by redesigning the target recognition sequence within IPH, which demonstrates the adaptable versatility‌ and substantial potential of the method in molecular diagnostics.
    Journal
    |
    MIR155 (MicroRNA 155)
    2d
    Structure-initiated CHA variant coordinating SDA for cascade amplification in CRISPR/Cas12a-based miRNA analysis. (PubMed, Talanta)
    The VCHA-SDA/Cas12a platform demonstrated excellent performance for miRNA-155 detection, achieving a broad dynamic range from 1 pmol/L to 10 nmol/L with an ultra-low detection limit of 0.166 pmol/L. Furthermore, the platform successfully quantified miRNA levels in clinical plasma specimens and various cell lines, confirming its considerable potential as a robust tool for molecular diagnostics and clinical translation.
    Journal
    |
    MIR155 (MicroRNA 155)
    4d
    Expression of MicroRNA-155 and its associations with EBV serological markers and inflammatory cytokines in young lymphoma patients with evidence of active EBV infection. (PubMed, Exp Biol Med (Maywood))
    These findings indicate that serum miR-155 is significantly elevated in young lymphoma patients with serological evidence of active EBV infection and is statistically associated with inflammatory cytokines, particularly IL-32. miR-155 may represent a promising non-invasive biomarker reflecting EBV-related immune activation, although tissue-based EBV confirmation and mechanistic studies are required to establish causality.
    Observational data • Journal
    |
    MIR155 (MicroRNA 155) • IL18 (Interleukin 18) • IL32 (Interleukin 32)
    4d
    Exosomal microRNAs as Central Regulators of Cancer Cachexia: Multi-Omics Insights into Muscle Wasting and Adipose Browning. (PubMed, J Proteome Res)
    This is the first integrated review linking exosomal miRNAs with proteomic and metabolomic signatures of cancer cachexia, offering a multiomics framework for biomarker discovery and therapeutic targeting. We highlight their potential as early biomarkers, therapeutic targets, and modulators of rehabilitation response, while outlining research gaps including limited clinical validation, intertumor heterogeneity, and the need for multiomics integration to advance translation into patient care.
    Review • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21) • MIR122 (MicroRNA 122) • MIR181A1 (MicroRNA 181a-1) • MIR183 (MicroRNA 183)
    6d
    Identification of Novel Hub Genes and Potential Signaling Pathways with the Pathogenesis of Oral Cavity Squamous Cell Carcinoma Based on Bioinformatics Analysis. (PubMed, Cancer Inform)
    It was revealed that the development and prediction of OSCC may be affected by hsa-mir-146a-5 and hsa-mir-155-5p. Novel potential biomarkers and signaling pathways associated with OSCC have been identified, which may be important in the transformation of OSCC adenocarcinoma and may serve as therapeutic targets for OSCC.
    Journal • IO biomarker
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • MIR155 (MicroRNA 155) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IL1B (Interleukin 1, beta) • TLR2 (Toll Like Receptor 2)
    10d
    PD-L1/CD274 and miR-155/MIR155HG Genetic Variants as Prognostic and Risk Biomarkers in Diffuse Large B-Cell Lymphoma. (PubMed, Cancers (Basel))
    In a hypothesis-generating manner, these findings suggest that PD-L1 genetic variants may predominantly influence disease progression and outcomes, while miR-155 variation may contribute to DLBCL susceptibility. These findings highlight germline immunogenetic variants as stable, treatment-independent markers that may inform future studies on risk stratification and prognosis in DLBCL.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MIR155 (MicroRNA 155)
    13d
    Gene Expression Profiling to Unveil Novel Biomarkers for Early Diagnosis and Therapies for Breast Cancer. (PubMed, Curr Top Med Chem)
    The stability of the top three receptor-ligand complexes was validated through molecular dynamics simulations. Therefore, our findings could be a valuable resource for researchers and medical professionals, aiding in BC diagnosis and treatment.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CAV1 (Caveolin 1) • MIR155 (MicroRNA 155) • CD34 (CD34 molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD36 (thrombospondin receptor) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    |
    Lynparza (olaparib) • lapatinib • Verzenio (abemaciclib) • Tukysa (tucatinib)
    13d
    Artificial neural network modeling and optimization of an electrochemical biosensor for plasma miR-155-based breast cancer detection. (PubMed, Sci Rep)
    The ANN-GA framework offers a practical and efficient strategy for biosensor development by reducing experimental iterations, thereby lowering material consumption and enabling rapid parameter optimization. These findings demonstrate that ANN-assisted optimization can accelerate the development of cost-effective, high-performance biosensors, supporting their translation into clinical diagnostics for early and accurate miR-155 detection.
    Journal
    |
    MIR155 (MicroRNA 155)
    19d
    A near-infrared-controlled and logic gate sensing platform for the sensitive and specific detection of dual miRNAs. (PubMed, RSC Adv)
    The biosensor demonstrated excellent sensitivity, with detection limits of 0.28 nM for miR-21 and 0.35 nM for miR-155. Validation in serum samples revealed recovery rates of 92-103.08%, confirming its potential for clinical application in complex biological environments.
    Journal
    |
    MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21)
    19d
    Cytokine MicroRNA regulatory networks in colorectal cancer: Contemporary research insights and mechanistic analysis. (PubMed, Cytokine Growth Factor Rev)
    Since the administration of targeted treatments can result in an immune-related adverse effect, growing interest has focused on exosomes as alternative carriers for miRNA-based therapeutics. Overall, applications of miRNAs have the potential to improve CRC outcomes.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR143 (MicroRNA 143) • MIR145 (MicroRNA 145)
    21d
    A Direct Near-Infrared Photocage-Blocked Methylation Gate Integrated with an Ultrasensitive Triple-Loop Self-Boosted Exponential Amplification DNA Nanocircuit for High-Fidelity Molecular Imaging. (PubMed, Anal Chem)
    When a model microRNA biomarker (miRNA-155) with elevated expression across various malignant tumors is used for proof-of-concept validation, we show the ultrahigh sensitivity and strong specificity of this fluorescent biosensor. More importantly, the bioanalytical toolbox enables high-fidelity molecular imaging in live-cell and in vivo scenarios, paving the way for the deployment of DNA nanocircuits in disease diagnosis.
    Journal
    |
    MIR155 (MicroRNA 155)
    23d
    Investigation of the Correlation Between Selected miRNAs, Proinflammatory Cytokines, and Serum Trace Elements in Bladder Cancer Development and Progression. (PubMed, Curr Issues Mol Biol)
    A significant positive correlation was detected between miRNA-34a and IL-6 and TGF-β (r = 0.294*, p = 0.010; r = 0.447**, p < 0.001). By evaluating these important biomarkers together, it might be possible to implement clinical applications for bladder cancer treatment and develop individual therapeutic strategies.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • TGFB1 (Transforming Growth Factor Beta 1)